Private Investors

Sofinnova Partners is an independent venture capital firm based in Paris. Over the past 40 years, the firm has financed and accompanied almost 500 companies.

They invest in start-ups, early-stage companies, corporate spin-offs and occasionally turnaround situations. They invest in Life Sciences (Biopharmaceuticals / Biotech, Medical Devices, Industrial Biotechnology) and in Clean Energy. Sofinnova Partners proactively sources deals, takes a lead role, is most often the first institutional investor in Round A financings, and leads its portfolio companies until exit. They sit on the boards of portfolio companies, and play an active role from the formation phase alongside entrepreneurs. They invest throughout Europe from headquarters in Paris with a portion of investments made in the rest of the world.

Founded in 1974, Sofinnova is a clinical-stage biopharmaceutical venture capital firm with approximately $2.2B under management. They are a passionate and committed team of MDs and PhDs that deploy human and financial capital to improve the lives of patients through science. Their mission is to provide industry leading venture returns by delivering transformative medicines to patients. They live their mission to deliver outstanding results for those they serve — patients, entrepreneurs, and the people and organisations that entrust them with their capital.

Sofinnova specialises in clinical and late preclinical investments in biopharmaceutical products. They actively partner with entrepreneurs across all stages of company formation including securing initial funding, building successful management teams, forming impactful corporate alliances, and navigating the M&A acquisition or IPOs' process. They seek to build world class companies that aspire to dramatically improve the current state of medical care today and ultimately, the lives of patients.

Morningside Group was founded in 1986, by the Chan family of Hong Kong, to make private equity and venture capital investments. The group is managed by investment professionals who are entrepreneurial, have deep industry knowledge and are effective in the local environment in which they operate. In addition to its investment activities, Morningside Group is strongly committed to social responsibility.

Alida Capital International (ACI) is a business angel syndicate. Launched in 2009 ACI is focused on investing in Scotland’s life sciences sector, specifically biotech and pharmaceutical companies.

ACI members have considerable entrepreneurial, financial and management experience in the biopharmaceutical sector, offering a flexible approach to funding.

They welcome approaches from startup and emerging biopharmaceutical companies who meet our investment criteria.

The Scottish Investment Bank (SIB) is a division of Scottish Enterprise that supports the development of Scotland’s private sector SME funding market to ensure both early stage and established businesses with growth and export potential have adequate access to growth capital.

SIB operates a suite of investment funds. The three equity funds adopt a highly innovative co-investment and shared risk intervention model to encourage more private investors to invest in early stage Scottish companies with high growth potential. SIB is also the lead investor in the privately managed Scottish Loan Fund which operates on a fully commercial basis and is aimed at established companies.